Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Buller

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Antiviral Research|September 16, 2021
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challengeScott Parker, June D'Angelo, R Mark Buller, et al.
Vaccine|November 9, 2010
VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response aloneLeonard Moise, R Mark Buller, Jill Schriewer, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Estimating Sedentary Breathing Rate from Chest-Worn Accelerometry From Free-Living DataBrian A Telfer, James R Williamson, Lara Weed, et al.
Journal of Virology|August 19, 2011
The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responsesCarolina R Melo-Silva, David C Tscharke, Mario Lobigs, et al.
Plos Pathogens|June 25, 2015
Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or ActivationJanet J Sei, Scott Haskett, Lauren W Kaminsky, et al.
Bioorganic & Medicinal Chemistry|April 16, 2011
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenineJacqueline Ruiz, James R Beadle, R Mark Buller, et al.
Antiviral Research|August 17, 2014
Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virusScott Parker, Ryan Crump, Scott Foster, et al.
Antiviral Research|October 6, 2009
Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxvirusesNadejda Valiaeva, Mark N Prichard, R Mark Buller, et al.
Plos One|June 8, 2010
Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesisShannon McNulty, William Bornmann, Jill Schriewer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2008
Structure and mechanism of IFN-gamma antagonism by an orthopoxvirus IFN-gamma-binding proteinAnthony A Nuara, Leigh J Walter, Naomi J Logsdon, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Antiviral Research|September 16, 2021
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challengeScott Parker, June D'Angelo, R Mark Buller, et al.
Vaccine|November 9, 2010
VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response aloneLeonard Moise, R Mark Buller, Jill Schriewer, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Estimating Sedentary Breathing Rate from Chest-Worn Accelerometry From Free-Living DataBrian A Telfer, James R Williamson, Lara Weed, et al.
Journal of Virology|August 19, 2011
The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responsesCarolina R Melo-Silva, David C Tscharke, Mario Lobigs, et al.
Plos Pathogens|June 25, 2015
Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or ActivationJanet J Sei, Scott Haskett, Lauren W Kaminsky, et al.
Bioorganic & Medicinal Chemistry|April 16, 2011
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenineJacqueline Ruiz, James R Beadle, R Mark Buller, et al.
Antiviral Research|August 17, 2014
Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virusScott Parker, Ryan Crump, Scott Foster, et al.
Antiviral Research|October 6, 2009
Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxvirusesNadejda Valiaeva, Mark N Prichard, R Mark Buller, et al.
Plos One|June 8, 2010
Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesisShannon McNulty, William Bornmann, Jill Schriewer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2008
Structure and mechanism of IFN-gamma antagonism by an orthopoxvirus IFN-gamma-binding proteinAnthony A Nuara, Leigh J Walter, Naomi J Logsdon, et al.
Pageof 6